DS
PIIIW icon

David Shaw’s P3 Health Partners Inc Warrant PIIIW Stock Holding History

David Shaw’s Portfolio PIIIW Stock Details PIIIW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,600
Closed -$9K – 5056
2022
Q3 		$9K Buy
+11,600
New +$8.33K ﹤0.01% 4953

Other funds holding PIIIW

LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
AC
Athos Capital Hong Kong $282M AUM 11.4% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return
PI
PEAK6 Investments Chicago, Illinois $44.8B AUM 19.99% 1-Year Est. Return

David Shaw's PIIIW Position: Q4 2022 in Review

David Shaw sold out of P3 Health Partners Inc Warrant (PIIIW) in Q4 2022, closing a stake of 11,600 shares — an estimated $9K sold.

David Shaw first reported a position in PIIIW in Q3 2022 and held it in 1 quarter. The position peaked at $9K in Q3 2022. 29 funds tracked by Wall St. Rank hold PIIIW as of Q4 2022.

  • David Shaw reported no remaining P3 Health Partners Inc Warrant position as of Q4 2022 after selling out during the quarter.
  • David Shaw sold 11,600 P3 Health Partners Inc Warrant shares in Q4 2022, an estimated $9K.
  • David Shaw first reported a position in P3 Health Partners Inc Warrant in Q3 2022 and held it in 1 quarter.
  • David Shaw's P3 Health Partners Inc Warrant position peaked at $9K in Q3 2022.
  • 29 funds tracked by Wall St. Rank held P3 Health Partners Inc Warrant as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.